Fatty Liver Index vs. Biochemical-Anthropometric Indices: Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease with Non-Invasive Tools

被引:0
|
作者
Demirci, Selim [1 ]
Sezer, Semih [1 ]
机构
[1] Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Gastroenterol, TR-06200 Ankara, Turkiye
关键词
anthropometry; metabolic dysfunction-associated steatotic liver disease (MASLD); non-invasive diagnosis; triglyceride-glucose index; fatty liver index;
D O I
10.3390/diagnostics15050565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a significant global burden, attributed to its increasing prevalence and strong correlation with metabolic syndrome and related conditions. Timely diagnosis and intervention are essential for minimizing the impact of MASLD. This study sought to analyze the efficacy of advanced anthropometric indices and non-invasive steatosis markers in diagnosing MASLD. Methods: This cross-sectional retrospective study evaluated the data from 578 Turkish patients admitted to our gastroenterology clinic. MASLD was diagnosed based on internationally recognized criteria. The evaluated parameters included body mass index (BMI); waist-hip ratio (WHR); waist-height ratio (WHtR); body roundness index (BRI); conicity index (CI); a body shape index (ABSI); visceral adiposity index (VAI); abdominal volume index (AVI); lipid accumulation product (LAP); fatty liver index (FLI); hepatic steatosis index (HSI); and triglyceride-glucose index (TyG) and its variants TyG-waist circumference(WC) and TyG-BMI. Results: Among 215 men, 103 (56.9%) met the criteria for MASLD, while 260 out of 363 women (65.5%) fulfilled the criteria. In the receiver operating characteristic (ROC) analysis for identifying MASLD, TyG-WC (0.826), TyG-BMI (0.820), and FLI (0.830) achieved the highest area under the curve (AUC) values, with statistically significant differences observed in their pairwise comparisons against the other parameters. Conclusions: TyG-WC and TyG-BMI are comparable to FLI in terms of simplicity of calculation and superior diagnostic accuracy, making them valuable non-invasive alternatives for MASLD screening and diagnosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Non-invasive testing in metabolic dysfunction-associated steatotic liver disease
    Dawod, Sanad
    Brown, Kimberly
    FRONTIERS IN MEDICINE, 2024, 11
  • [2] Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
    Gambardella, Maria Luisa
    Abenavoli, Ludovico
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
  • [3] Non-invasive assessment of metabolic dysfunction-associated fatty liver disease
    Chandra Kumar, C. Vikneshwaran
    Skantha, Ruben
    Chan, Wah-Kheong
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [4] Performance of non-invasive indexes in the assessment of metabolic dysfunction-associated steatotic liver disease
    Yague Parada, Alvaro
    Castaneda Agredo, Andres Felipe
    Calvo Hernandez, Rocio
    Gonzalez Guirado, Agustina
    Varela Silva, Andres
    Moran Ortiz de Solorzano, Marta
    Casanova Cabral, Michelle
    Polo Lorduy, Benjamin
    JOURNAL OF HEPATOLOGY, 2024, 80 : S599 - S599
  • [5] Non-invasive biomarkers of liver fibrosis may be used for diagnosing fibrosis and prognostication in patients with metabolic dysfunction-associated steatotic liver disease
    Hetland, Liv Eline
    Werge, Mikkel
    Thing, Mira
    Rashu, Elias
    Nabilou, Puria
    Kimer, Nina
    Junker, Anders
    Leeming, Diana
    Karsdal, Morten
    Guiliani, Alejandro Mayorca
    Gluud, Lise Lotte
    JOURNAL OF HEPATOLOGY, 2024, 80 : S513 - S513
  • [6] Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease
    Qu, Biao
    Li, Zheng
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (28)
  • [7] Suitability of non-invasive tests in the evaluation of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
    Yague Parada, Alvaro
    Castaneda Agredo, Andres Felipe
    Calvo Hernandez, Rocio
    Gonzalez Guirado, Agustina
    Varela Silva, Andres
    Moran Ortiz de Solorzano, Marta
    Casanova Cabral, Michelle
    Polo Lorduy, Benjamin
    JOURNAL OF HEPATOLOGY, 2024, 80 : S598 - S598
  • [8] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [9] Biochemical and Anthropometric Indices of Insulin Resistance in Obese and Overweight Children with Metabolic Dysfunction-Associated Fatty Liver Disease
    Trochimczyk, Kinga
    Flisiak-Jackiewicz, Marta
    Bobrus-Chociej, Anna
    Lebensztejn, Anna
    Wojtkowska, Malgorzata
    Jamiolkowski, Jacek
    Lebensztejn, Dariusz Marek
    MEDICAL SCIENCE MONITOR, 2024, 30 : e943375
  • [10] METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): CONCORDANCE OF CLINICAL PROFILES AND NON-INVASIVE TESTS PERFORMANCE
    Stepanova, Maria
    De Avila, Leyla
    Racila, Andrei
    Golabi, Pegah
    Nader, Fatema
    Younossi, Zobair M.
    GASTROENTEROLOGY, 2024, 166 (05) : S1558 - S1558